If our finding is confirmed by gene expression data in a future study, then one may consider investigating the effect of TNFR2-targeted antibody therapy in BRAF mutant thyroid cancer patients in the case of RAI failure. This evidence concerns the gene TNFRSF1B and thyroid gland carcinoma.